

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17638 (BOT)	SERIAL NO.: PENDING
APPLICANT DIMITROVA, ET AL..	TITLE: BOTULINUM TOXIN INJECTION GUIDE
FILING DATE: HEREWITH	GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
BH	AA	10/621,054	7/15/03	Caers, et al.			July 15, 2003
	AB	5,437,291	8/1/1995	Pasricha et al.			
	AC	5,670,484	9/23/1997	Binder			
	AD	5,714,468	2/3/1998	Binder			
	AE	5,766,605	6/16/1998	Sanders et al.			
	AF	6,063,768	5/16/2000	First			
	AG	6,063,768	5/16/2000	First			
	AH	6,113,915	9/5/2000	Aoki et al.			
	AI	6,139,845	10/31/2000	Donovan			
	AJ	6,143,306	11/7/2000	Donovan			
	AK	6,265,379	7/24/2001	Donovan			
	AL	6,299,893	10/9/2001	Schwartz et al.			
	AM	6,306,403	10/23/2001	Donovan			
	AN	6,306,423	10/23/2001	Donovan et al.			
	AO	6,312,708	11/6/2001	Donovan			
	AP	6,328,977	12/11/2001	Donovan			
	AQ	6,358,513	3/19/2002	Voet et al.			
	AR	6,365,164	4/2/2002	Schmidt			
	AS	6,395,277	5/28/2002	Graham			
	AT	6,423,319	7/23/2002	Brooks et al.			
	AU	6,458,365	10/1/2002	Aoki et al.			
	AV	6,464,986	10/15/2002	Aoki et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/n)
	BA	NONE					

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Aoki K.R., <i>Pharmacology and immunology of botulinum toxin serotypes</i> , J Neurol 248(suppl 1), 1/3-1/10, 2001
CB	Aoki KB, Cui M, <i>Mechanisms of the Antinociceptive Effect of Subcutaneous BOTOX®: Inhibition of Peripheral and Central Nociceptive Processing</i> , Cephalalgia 23(7);649:2003

EXAMINER Bajin

DATE CONSIDERED 2/23/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17638 (BOT)	SERIAL NO.: PENDING
APPLICANT DIMITROVA, ET AL..	TITLE: BOTULINUM TOXIN INJECTION GUIDE
FILING DATE: HEREWITH	GROUP

BHH	CC	Argoff, A <i>Focused Review on the Use of Botulinum Toxins for Neuropathic Pain</i> , Clin J Pain 18(6 Suppl);S177-S181:2002
BHH	CD	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360;318-324:1985
BHH	CE	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
BHH	CF	Binz T. et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> , J Biological Chemistry 265(16);9153-9158:1990
BHH	CG	Bushara K., <i>Botulinum toxin and rhinorrhea</i> , Otolaryngol Head Neck Surg 1996;114(3):507
BHH	CH	Cui M, Aoki KR, <i>Botulinum toxin type a (BTX-a) reduced inflammatory pain in the rat formalin model</i> , Cephalalgia 20(4);414:2000
BHH	CI	Cui M, Li Z, You S, Khanijou S, Aoki KR, <i>Mechanisms of Antinociceptive Effect of Subcutaneous BOTOX®: Inhibition of Peripheral and Central Nociceptive Processing</i> , Naunyn Schmiedegergs Arch Pharmacol 265(Suppl 2);R17:2002
BHH	CJ	Duggan, J.J., et al., <i>Mov Disord</i> , 10(3):376:1995
BHH	CK	Durham P, Cady R, Cady R, <i>Mechanism of botulinum toxin type-A Inhibition of Calcitonin Gene-Related Peptide Secretion from Trigeminal Nerve Cells</i> , Cephalalgia 23(7);690:2003
BHH	CL	Gonelle-Gispert, C., et al., <i>SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion</i> , Biochem J 1;339 (pt 1): 159-65:1999
BHH	CM	Grimalt, R., <i>Multi-injection plate for botulinum toxin application in the treatment of axillary hyperhidrosis</i> , Dermatol Surg 2001 Jun;27(6): 543-544
BHH	CN	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the release of [³H]Noradrenaline and [³H]GABA From Rat Brain Homogenate</i> , Experientia 44;224-226:1988
BHH	CO	Habermann, E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , J Neurochem 51(2);522-527:1988)
	CP	Habermann, Naunyn-Schmiedeberg's Arch. Pharmacol. 1974, 281, 47-56
BHH	CQ	Jankovic J. et al., <i>Therapy With Botulinum Toxin</i> , Marcel Dekker, Inc., (1994), page 5
BHH	CR	Marchese-Ragona, R., et al., <i>Management of parotid sialoceles with botulinum toxin</i> , The Laryngoscope, Aug. 109(8):1344-1346:1999
BHH	CS	Moyer, et al., <i>Botulinum toxin type B: experimental and clinical experience</i> , Ch. 6, pgs. 71-85, <i>Therapy with Botulinum Toxin</i> , ed. Jankovic, J., et al. (1994) Marcel Dekker, Inc.
BHH	CT	Naumann, M., et al., <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> , European J. Neurology 6 (Supp 4): S111-S1150:1999
BHH	CU	Pearce, L.B., <i>Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine</i> , Toxicon 35(9);1373-1412 at 1393
BHH	CV	Sanchez-Prieto, J., et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , Eur J. Biochem 165;675-681:1987

EXAMINER [Signature]

DATE CONSIDERED 2/23/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT


ATTY. DOCKET: 17638 (BOT)	SERIAL NO.: PENDING
APPLICANT DIMITROVA, ET AL..	TITLE: BOTULINUM TOXIN INJECTION GUIDE
FILING DATE: HEREWITH	GROUP

BHH	CW	Shantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , Microbiol Rev. 56:80-99:1992
BHH	CX	Singh, B.R., et al. <i>Critical aspects of bacterial protein toxins</i> , Natural Toxins II, Ch. 4, edited by B.R. Singh, et al., Plenum Press, New York (1976), pgs. 63-84
BHH	CY	Sloop, R.R., et al., <i>Reconstituted botulinum toxin type A dose not lose potency I humans if it is refrozen or refrigerated for 2 weeks before use.</i> , Neurology, 48:249-53:1997
BHH	CZ	Weigand et al, <i>Nauny-Schmiedeberg's Arch. Pharmacol.</i> 1976; 292, 161-165

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17638 (BOT)	SERIAL NO.: 10/748,999
APPLICANT DIMITROVA, ET AL.	TITLE: BOTULINUM TOXIN INJECTION GUIDE
FILING DATE: DECEMBER 29, 2003	GROUP 3763

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
BH	AA	4,642,096	02/10/1987	KATZ	604	116	
	AB	6,322,536 B1	11/27/2001	ROSENGART et al	604	164.01	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
BH	BA	WO 02/068028 A1	02/27/2001	PCT	A61M	5/42	Y
	BB	WO 80/00060	06/18/1979	PCT	A61M	5/00	Y
	BC						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	NONE
	CB	
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	

EXAMINER BH

DATE CONSIDERED 2/23/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.